MariMed Inc. Reports Record Revenue for 2025, Announces Strategic Developments and Strengthened Balance Sheet

Key Financial and Operational Highlights for Investors

MariMed Inc. (OTCQX: MRMD), a leading multi-state cannabis operator, has released its fourth quarter and full year 2025 earnings results, demonstrating resilience and growth in a challenging market environment. The company reported its sixth consecutive year of positive Adjusted EBITDA and took significant steps to bolster its balance sheet. Below are the detailed highlights, insights, and potential impacts for shareholders.

1. Financial Performance Overview

• Record Revenue: MariMed achieved a record annual revenue of \$159.8 million for 2025, marking a slight increase from \$157.7 million in 2024.
• Adjusted EBITDA: The company delivered positive Adjusted EBITDA of \$16.9 million, maintaining profitability for the sixth straight year, though this was a decrease from \$19.3 million in 2024.
• Wholesale Strength: Wholesale revenue increased by 11%, and MariMed expanded its distribution to 85% of dispensaries in its core markets.
• Brand Leadership: The flagship Betty’s Eddies™ fruit chews remained the top-selling edible in Massachusetts, Maryland, Delaware, and Illinois. The Vibations™ drink mix ranked fourth among cannabis beverages in these states.
• Gross Margins and Net Loss: Non-GAAP gross margin was 41% for the year, down from 43% in 2024. The company reported a non-GAAP net loss of \$2.9 million for 2025, compared to a non-GAAP net loss of \$3.6 million in 2024. The GAAP net loss increased to \$14.5 million from \$12.4 million in 2024.
• Liquidity: MariMed ended 2025 with \$8.9 million in cash, up from \$7.3 million at the end of 2024. The company generated \$7.7 million in cash from operating activities, compared to \$6.8 million the previous year.

2. Key Strategic and Operational Developments

• Series B Convertible Preferred Stock Restructuring: In March 2026, MariMed restructured its \$14.7 million Series B obligation, extending its maturity by 4.6 years. This move eliminates any near-term mandatory conversion, reduces refinancing risk, and enhances liquidity, which is a significant positive for the company’s capital structure and financial flexibility.
• Geographic Expansion:
  • Signed a licensing agreement with Farm 2 Hand, LLC, a New York State cannabis license holder, enabling MariMed to enter the New York market once regulatory approvals are secured.
  • Launched brand distribution in Maine via a new licensing partner during Q4 2025.
  • Plans to open a new dispensary in Columbus, Ohio in 2026, adding to the company’s retail footprint.
  • Exited the Missouri market in October 2025 to refocus resources on higher-return core markets.
• Product Innovation: Announced manufacturing and distribution agreements for Vibations™ beverage brand to enter the hemp-derived THC market, starting in Rhode Island in 2026.

3. Outlook for 2026 and Beyond

• The company expects further revenue growth driven by a full year of adult-use cannabis sales in Delaware, expansion in Maine, and contributions from the new Ohio dispensary.
• Management remains focused on protecting margins, prioritizing high-return capital deployment, and maintaining strong liquidity to navigate industry volatility and emerging opportunities.

4. Balance Sheet and Financial Position

• Total Assets: \$202.6 million as of December 31, 2025.
• Total Liabilities: \$137.8 million.
• Stockholders’ Equity: \$50.0 million, up from \$48.2 million at the end of 2024.
• Reduced Near-Term Debt Pressure: The restructuring of preferred stock and low near-term debt maturities provide the company with enhanced financial flexibility.

5. Additional Shareholder-Relevant Details

• Conference Call: MariMed management will host a call on March 12, 2026, at 8:00 a.m. ET to discuss the results and outlook.
• Non-GAAP Metrics: Investors are encouraged to review non-GAAP financial measures as they provide a clearer picture of operational performance by excluding items like depreciation, amortization, stock-based compensation, and one-off charges.
• Risks & Forward-Looking Statements: The company notes ongoing risks including regulatory changes, consumer demand, and industry volatility. Recent and future performance may be impacted by these factors.

Potential Share Price Movers

• Record revenue and improved operating cash flow in a difficult market may boost investor confidence.
• Restructuring of preferred stock significantly reduces refinancing risk and could be viewed positively by the market.
• Strategic exits and market entries (e.g., New York, Maine, Ohio, and exit from Missouri) demonstrate a focus on high-return opportunities and prudent capital allocation.
• Continued brand leadership with top-selling products should underpin future growth and market share gains.

Conclusion

MariMed’s 2025 results highlight disciplined execution, strategic expansion, and a focus on financial stability, even as the broader cannabis industry faces pricing pressures and regulatory uncertainties. The restructuring of its Series B obligation, brand leadership, and ongoing geographic expansion are all catalysts that could impact the company’s market valuation.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with a qualified financial advisor before making investment decisions. All statements regarding future performance are forward-looking and subject to risks and uncertainties.

View MARIMED INC. Historical chart here